Insilico Medicine advances AI-discovered IPF drug to Phase III

Insilico Medicine is moving its AIdiscovered drug rentosertib into Phase III trials for idiopathic pulmonary fibrosis (IPF), a severe lung disease that causes progressive scarring and reduced breathing capacity. The company says the program has already passed earlier safety and midstage testing and is now entering the larger trial stage needed to assess efficacy. In a randomized study across 22 clinical sites in China, 71 patients received either placebo or daily doses of 30 mg or 60 mg for 12 weeks. The 60 mg group showed a mean improvement in forced vital capacity of 98.4 mL, while the placebo group declined by 20.3 mL. Reported safety findings were described as manageable, and the drug has received FDA orphan drug designation. The company says rentosertib was identified through its Pharma.AI platform, which combines target discovery, generative chemistry, and biological analysis to guide drug design. Insilico positions the Phase III trial as an important test of whether AIbased drug discovery can deliver measurable clinical benefit in humans.